279 related articles for article (PubMed ID: 24317512)
1. CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.
Delehouzé C; Godl K; Loaëc N; Bruyère C; Desban N; Oumata N; Galons H; Roumeliotis TI; Giannopoulou EG; Grenet J; Twitchell D; Lahti J; Mouchet N; Galibert MD; Garbis SD; Meijer L
Oncogene; 2014 Dec; 33(50):5675-87. PubMed ID: 24317512
[TBL] [Abstract][Full Text] [Related]
2. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases.
Bettayeb K; Oumata N; Echalier A; Ferandin Y; Endicott JA; Galons H; Meijer L
Oncogene; 2008 Oct; 27(44):5797-807. PubMed ID: 18574471
[TBL] [Abstract][Full Text] [Related]
3. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.
Molenaar JJ; Ebus ME; Geerts D; Koster J; Lamers F; Valentijn LJ; Westerhout EM; Versteeg R; Caron HN
Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12968-73. PubMed ID: 19525400
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
Dolman ME; Poon E; Ebus ME; den Hartog IJ; van Noesel CJ; Jamin Y; Hallsworth A; Robinson SP; Petrie K; Sparidans RW; Kok RJ; Versteeg R; Caron HN; Chesler L; Molenaar JJ
Clin Cancer Res; 2015 Nov; 21(22):5100-9. PubMed ID: 26202950
[TBL] [Abstract][Full Text] [Related]
7. Casein kinase 1ε and 1α as novel players in polycystic kidney disease and mechanistic targets for (R)-roscovitine and (S)-CR8.
Billot K; Coquil C; Villiers B; Josselin-Foll B; Desban N; Delehouzé C; Oumata N; Le Meur Y; Boletta A; Weimbs T; Grosch M; Witzgall R; Saunier S; Fischer E; Pontoglio M; Fautrel A; Mrug M; Wallace D; Tran PV; Trudel M; Bukanov N; Ibraghimov-Beskrovnaya O; Meijer L
Am J Physiol Renal Physiol; 2018 Jul; 315(1):F57-F73. PubMed ID: 29537311
[TBL] [Abstract][Full Text] [Related]
8. CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells.
Bettayeb K; Baunbæk D; Delehouze C; Loaëc N; Hole AJ; Baumli S; Endicott JA; Douc-Rasy S; Bénard J; Oumata N; Galons H; Meijer L
Genes Cancer; 2010 Apr; 1(4):369-80. PubMed ID: 21779453
[TBL] [Abstract][Full Text] [Related]
9. Cep63 recruits Cdk1 to the centrosome: implications for regulation of mitotic entry, centrosome amplification, and genome maintenance.
Löffler H; Fechter A; Matuszewska M; Saffrich R; Mistrik M; Marhold J; Hornung C; Westermann F; Bartek J; Krämer A
Cancer Res; 2011 Mar; 71(6):2129-39. PubMed ID: 21406398
[TBL] [Abstract][Full Text] [Related]
10. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
11. N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine.
Bettayeb K; Sallam H; Ferandin Y; Popowycz F; Fournet G; Hassan M; Echalier A; Bernard P; Endicott J; Joseph B; Meijer L
Mol Cancer Ther; 2008 Sep; 7(9):2713-24. PubMed ID: 18790752
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
Cosimo E; McCaig AM; Carter-Brzezinski LJ; Wheadon H; Leach MT; Le Ster K; Berthou C; Durieu E; Oumata N; Galons H; Meijer L; Michie AM
Clin Cancer Res; 2013 May; 19(9):2393-405. PubMed ID: 23532892
[TBL] [Abstract][Full Text] [Related]
13. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
Rounbehler RJ; Li W; Hall MA; Yang C; Fallahi M; Cleveland JL
Cancer Res; 2009 Jan; 69(2):547-53. PubMed ID: 19147568
[TBL] [Abstract][Full Text] [Related]
14. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
[TBL] [Abstract][Full Text] [Related]
15. Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
Puissant A; Frumm SM; Alexe G; Bassil CF; Qi J; Chanthery YH; Nekritz EA; Zeid R; Gustafson WC; Greninger P; Garnett MJ; McDermott U; Benes CH; Kung AL; Weiss WA; Bradner JE; Stegmaier K
Cancer Discov; 2013 Mar; 3(3):308-23. PubMed ID: 23430699
[TBL] [Abstract][Full Text] [Related]
16. NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas.
Suenaga Y; Islam SM; Alagu J; Kaneko Y; Kato M; Tanaka Y; Kawana H; Hossain S; Matsumoto D; Yamamoto M; Shoji W; Itami M; Shibata T; Nakamura Y; Ohira M; Haraguchi S; Takatori A; Nakagawara A
PLoS Genet; 2014 Jan; 10(1):e1003996. PubMed ID: 24391509
[TBL] [Abstract][Full Text] [Related]
17. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.
Chipumuro E; Marco E; Christensen CL; Kwiatkowski N; Zhang T; Hatheway CM; Abraham BJ; Sharma B; Yeung C; Altabef A; Perez-Atayde A; Wong KK; Yuan GC; Gray NS; Young RA; George RE
Cell; 2014 Nov; 159(5):1126-1139. PubMed ID: 25416950
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
Chen Y; Tsai YH; Tseng SH
Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.
Chesler L; Schlieve C; Goldenberg DD; Kenney A; Kim G; McMillan A; Matthay KK; Rowitch D; Weiss WA
Cancer Res; 2006 Aug; 66(16):8139-46. PubMed ID: 16912192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
